At Hemova, we work in the responsible commercialization of plasma-derived medicines for orphan and rare diseases, coagulation disorders, and situations requiring plasma volume support.
Our work connects patients, medical teams, and healthcare institutions around a shared goal: achieving safe, timely, and sustainable treatments.
At Hemova, we understand that behind every diagnosis there are stories, families, and life projects. That is why we aim to be a trusted partner to the healthcare system - bringing together scientific knowledge and a human perspective. Staying up to date, listening to stakeholders across the system, and acting transparently are essential to how we work.
To bring highly specialized, innovative therapies to people living with orphan and rare diseases, coagulation disorders, and high clinical-impact conditions - working alongside Colombia's healthcare system to support access, appropriate use, and treatment safety.
To be a leading reference company in Latin America in the management of innovative therapies for orphan, rare, and high-cost diseases - recognized for our commitment to patients, alignment with scientific evidence, and coordinated work with healthcare institutions and professionals.
Hemova's work is grounded in principles that guide our daily decisions and the way we engage with patients, institutions, and healthcare professionals.
We consider the real impact that orphan, rare, and high-cost diseases have on people's lives. That is why we prioritize safety, continuity, and quality in everything we do - so therapies can meaningfully improve patients' quality of life.
We promote the use of innovative therapies supported by clinical data and current regulatory frameworks, maintaining an ongoing review of the available evidence.
We collaborate with institutions, payers, and medical teams to facilitate clear processes, support risk management, and contribute to the responsible use of resources.
We safeguard quality throughout the entire value chain and implement pharmacovigilance mechanisms that allow us to detect, assess, and report potential adverse events in line with regulatory requirements.
We listen to the needs of patients, institutions, and medical teams.
We provide evidence-based information and maintain ongoing dialogue.
We monitor safety through our pharmacovigilance processes.
We work in an integrated manner with specialists, laboratories, and care centers to ensure each patient receives a comprehensive and personalized approach.
Our work is built on long-term, trust-based relationships. This means understanding the needs of different clinical settings, providing clear information, and being available to address questions about our therapeutic areas and the responsible use of the medicines we commercialize.
From portfolio selection to product availability, we aim to integrate clinical, technical, and regulatory perspectives. In doing so, we support the healthcare system in informed decision-making and in pursuing better outcomes for people living with complex diseases.
We look ahead with the goal of further strengthening access to highly specialized, innovative therapies and contributing to the management of orphan, rare, and high-cost diseases. At Hemova, we will continue working to be a trusted ally to the healthcare system and a source of support for those living with these conditions and their families.
